G8 Education Limited (ASX:GEM) Responds to ASX Aware Letters
G8 Education Limited (ASX:GEM) addresses ASX’s aware letters concerning an employee charge and subsequent stock price decline.
Tag: Regulatory News & Compliance
Imugene Limited (ASX:IMU) Announces Positive Phase 1b Trial Results for Azer-cel
Imugene Limited (ASX:IMU) reports 75% response rate in Phase 1b trial of azer-cel for relapsed diffuse large B-cell lymphoma.
Orthocell Limited (ASX:OCC) Reports First US Remplir™ Sales Revenue
Orthocell (ASX:OCC) records first US sales revenue from Remplir™ nerve repair product, marking a significant milestone in US expansion.
Resolution Minerals (ASX:RML) Receives Drilling Permits and Advances Acquisition of Horse Heaven Project
Resolution Minerals (ASX:RML) secures drilling permits for Horse Heaven Project and progresses acquisition, with drilling set to begin in August 2025.
Wrkr Ltd (ASX:WRK) and MUFG Extend Partnership to Enhance AustralianSuper Services
Wrkr Ltd (ASX:WRK) extends its partnership with MUFG Retirement Solutions to deliver a new digital platform for AustralianSuper, enhancing superannuation services.
Australian Pacific Coal Limited (ASX:AQC) Suspended from Quotation
Australian Pacific Coal Limited (ASX:AQC) suspends ASX trading pending updates on Dartbrook Mine operations and financial assessments.
Ionic Rare Earths Limited (ASX:IXR) Responds to ASX Price Query
Ionic Rare Earths Limited (ASX:IXR) responds to ASX’s price query, citing recent operational updates and a $3m capital raise as factors behind trading activity.
Argosy Minerals Limited (ASX: AGY) Initiates Trading Halt Pending Capital Raising
Argosy Minerals (ASX:AGY) requests a trading halt pending a capital raising announcement, effective until July 8, 2025.
Capricorn Metals Limited (ASX:CMM) Reports Strong Q4 Gold Production
Capricorn Metals Limited (ASX:CMM) reports Q4 gold production of 32,216 ounces, meeting annual guidance and advancing expansion projects.
Imugene Limited (ASX:IMU) Receives $5.8m R&D Tax Refund
Imugene Limited (ASX:IMU) receives a A$5.8m R&D tax refund to advance its immuno-oncology pipeline.